Medexus PharmaceuticalsMEDXF +3.96%60 Days Payable is 206.89 as of Mar. 2026, which is 118% above its 10-year median of 94.78. GuruFocus rates MEDXF with a GF Score™ of 60/100 and a GF Value™ of $1.32 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 922 Drug Manufacturers companies, Medexus Pharmaceuticals ranks better than 87.09% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Medexus Pharmaceuticals's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medexus Pharmaceuticals Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Medexus Pharmaceuticals's Days Payable distribution charts can be found below:
* The bar in red indicates where Medexus Pharmaceuticals's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Medexus Pharmaceuticals's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medexus Pharmaceuticals (MEDXF) has a Days Payable of 206.89 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Medexus Pharmaceuticals and its competitors. This is 118% above median its historical median of 94.78. Over the past decade, Medexus Pharmaceuticals' Days Payable has ranged from 45.98 to 219.43. According to the industry distribution chart, Medexus Pharmaceuticals ranks #119 out of 922 companies in the Drug Manufacturers industry, placing it in the top 12.9%.
Is Medexus Pharmaceuticals' Days Payable too high?
Medexus Pharmaceuticals' current Days Payable of 206.89 is 118% above median its 10-year median of 94.78. Over the past 10 years, this metric has ranged from a low of 45.98 to a high of 219.43. The Drug Manufacturers industry median Days Payable is 90.84. Medexus Pharmaceuticals' value of 206.89 is 127.8% above this industry median. Based on the distribution chart, Medexus Pharmaceuticals ranks #119 out of 922 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Medexus Pharmaceuticals has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medexus Pharmaceuticals' Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Medexus Pharmaceuticals ranks #119 out of 922 companies for Days Payable. This places Medexus Pharmaceuticals in the top 13% of its industry — outperforming the majority of peers. The industry median Days Payable is 90.84. Medexus Pharmaceuticals' value of 206.89 is 127.8% above this benchmark. Historically, Medexus Pharmaceuticals' own Days Payable has ranged from 45.98 to 219.43 over the past decade. While the company's 10-year median is 94.78 vs. the industry median of 90.84, Medexus Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.84, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medexus Pharmaceuticals's current Days Payable of 206.89 is 127.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Medexus Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medexus Pharmaceuticals's current Days Payable is 206.89, which is 118% above median its own 10-year median of 94.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medexus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Medexus Pharmaceuticals (MEDXF) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.32, compared to a current price of $3.62 — trading 174.2% above its estimated fair value. The current Days Payable is 206.89, which is 118% above median its 10-year median of 94.78 and 127.8% above the Drug Manufacturers industry median of 90.84. Medexus Pharmaceuticals' overall GF Score™ is 60/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Medexus Pharmaceuticals (MEDXF), the current Days Payable is 206.89 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medexus Pharmaceuticals (MEDXF) Overvalued in 2026?
Based on GuruFocus' analysis, Medexus Pharmaceuticals stock appears to be overvalued.
The current stock price of $3.62 is trading 174.2% above its estimated GF Value™ of $1.32.
GuruFocus considers Medexus Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for MEDXF:
Days Payable: 206.89 (118% above median its 10-year median of 94.78)
GF Value™: $1.32 vs. price of $3.62 (174.2% above fair value)
Industry Position: 127.8% above the Drug Manufacturers median (#119 of 922)
No single metric tells the full story. See the MEDXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medexus Pharmaceuticals Inc is a specialty pharmaceutical company with a powerful North American commercial platform and a growing portfolio of inventive and rare disease treatment solutions. The company's focus is on the therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Medexus products are generally sold in North America to wholesalers, distributors, government agencies, healthcare facilities and specialty pharmacies.
60GF Score
Get the complete analysis for MEDXF
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEDXF has been successfully added to your 
